Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 14/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 13/20 | 0.34 |
| ▸ | CD38 | P28907 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5999051 | 1.00 | PRKCQ (0.35) | PRKCQPRKCDCD38SMN1; SMN2CYP1A2 | |
| SCHEMBL5002028 | 0.90 | PRKCQ (0.38) | PRKCQPRKCDSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL4472726 | 0.84 | PRKCQ (0.44) | PRKCQSMN1; SMN2LMNAALDH1A1HPGD | |
| SCHEMBL4477995 | 0.83 | PRKCQ (0.40) | PRKCQPRKCDCD38SMN1; SMN2LMNA | |
| SCHEMBL4474922 | 0.81 | PRKCQ (0.37) | PRKCQPRKCDSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL5177096 | 0.79 | PRKCQ (0.58) | PRKCQPRKCDCYP3A4CYP2C9 | |
| SCHEMBL5002034 | 0.78 | — | — | |
| SCHEMBL3814212 | 0.74 | PRKCQ (0.58) | PRKCQPRKCDCYP3A4CYP2C9LMNA | |
| SCHEMBL4471874 | 0.72 | PRKCQ (0.45) | PRKCQSMN1; SMN2LMNAALDH1A1HPGD | |
| SCHEMBL4490685 | 0.71 | PRKCQ (0.41) | PRKCQSMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601714-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20060025433-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025433-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | PRKCZ, PRKCQ, PRKCH | PRKCQ 2/4885PRKCD 9/4885CD38 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.